IMS's Incivek reporting hitch spurs stock swing

IMS Health continues to assess a data-supply glitch that led to an underreporting of ­prescriptions for Vertex Pharmaceuticals' hepatitis C drug Incivek.

During the period in question—the last two weeks of September—IMS data showed relatively flat TRx of the drug. Various financial analysts interpreted the dip as a sign that usage of the new drug had peaked.

Instead, IMS said, a key supplier had missed some mail order prescriptions. IMS adjusted for the issue but due to the short duration is not restating the history, a spokseman for the company said.

But when the company initially disclosed the hitch, Vertex shares jumped 7% as investors expected that a new sales report would reflect more comprehensive estimates. Then, when new IMS data still did not show sales had risen, shares declined by more than 6%.

As of early October, Incivek scripts continued to climb. Vertex is battling Merck's Victrelis for hep-C market share.

Because of IMS's script-reporting issues, rival Rx tracker Wolters Kluwer said it verified the quality of data it received from vendors for Incivek and Victrelis, saying it had not experienced a significant loss of data and continued to receive “a consistent data flow.”

A Vertex spokesperson said the firm doesn't comment on IMS data.
You must be a registered member of MMM to post a comment.

Next Article in Features

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters